Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines

Clinical Infectious Diseases

Volumn 35, Issue 10, 2002, Pages 1147-1154

  Faucher, Jean François ^a   Binder, Ronnie ^a,b   Missinou, Michel A ^a,b   Matsiegui, Pierre Blaise ^a   Gruss, Holger ^a   Neubauer, Rajko ^a   Lell, Bertrand ^a,b   Que, John U ^c   Miller, Gerri B ^d   Kremsner, Peter G ^a,b  

^a Albert Schweitzer Hospital   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Berna Biotech   (Switzerland)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; CHOLERA VACCINE; CYCLOGUANIL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVE VACCINE; TYPHOID VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; CHILDHOOD DISEASE; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEMALE; FEVER; GABON; HEADACHE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALMONELLA TYPHI; TYPHOID FEVER; VIBRIO CHOLERAE; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIMALARIALS; ATOVAQUONE; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; CHLOROGUANIDE; CHOLERA VACCINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNITY; MALARIA; MALE; NAPHTHOQUINONES; TREATMENT OUTCOME; TYPHOID-PARATYPHOID VACCINES;

EID: 0037111628     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342908     Document Type: Article

References (32)

1. Behrens RH, Roberts JA. Is travel prophylaxis worthwhile? Economic appraisal of prophylactic measures against malaria, hepatitis A and typhoid in travellers. BMJ 1994; 309:918-22.
2. Levine MM, Ferreccio E, Abrego P, San Martin O, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999; 17:S22-7.
3. Ryan ET, Calderwood SB. Cholera vaccines. Clin Infect Dis 2000; 31: 561-5.
4. Wolfe MS. Precautions with oral live typhoid (Ty21A) vaccine. Lancet 1990; 336:631-2.
5. Horowitz H, Carbonaro CA. Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis 1992; 166:1462-4.
6. Ambrosch F, Hirschl A, Kremsner P, et al. Orale Typhus-Lebendimpfung. Munch Med Wochenschr 1985; 127:775-8.
7. Ambrosch F, Hirschl A, Kollaritsch H, Kremsner P, Rappold E, Wiedermann G. Untersuchungen zur Kompatibilität des neuen Malaria-mittels Mefloquin mit der oralen Typhus-Lebendimpfung. Mitt Osterr Ges Tropenmed Parasitol 1987; 9:167-72.
8. Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis 1997; 175:871-5.
9. Pappaiouanou M, Fishbein DB, Dreesen DW, et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986; 314:280-4.
10. Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil for suppressive prophylaxis against Plasmodiumfalciparum malaria. Clin Infect Dis 1998; 27:494-9.
11. Sukwa TY, Mulenga M, Chisaka N, Roskell NS, Scott TR. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999; 60:521-5.
12. Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomized placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709-13.
13. Høgh B, Clarke PD, Camus D, et al., and the Malarone International Study Team. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: A randomised, double-blind study. Lancet 2000; 356:1888-94.
14. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: Results from a randomized, double-blind study. Clin Infect Dis 2001; 33:1015-21.
15. Shanks GD, Kremsner PG, Sukwa TY, et al., for the Malarone Clinical Trials Study Group. Atovaquone and proguanil hydrochloride for prophylaxis of malaria. J Travel Med 1999; 6(Suppl 1):S21-7.
16. Wildling E, Winkler S, Kremsner PG, et al. Malaria epidemiology in the Province of Moyen Ogooué, Gabon. Trop Med Parasitol 1995; 46: 77-82.
17. Kremsner PG, Winkler S, Brandts C, Neifer S, Bienzle U, Graninger W. Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis 1994; 169:467-70.
18. Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Rocha RM. A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil. J Infect Dis 1988; 158:1368-71.
19. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther 1997; 61:518-30.
20. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ. Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Br J Clin Pharmacol 1996; 42:589-97.
21. Cryz SJ Jr, Que JU, Levine MM, Wiedermann G, Kollaritsch H. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect Immun 1995; 63:1336-9.
22. Clements ML, Levine MM, Young CR, Black RE, Lim YL, Robins-Browne RM. Magnitude, kinetics and duration of vibriocidal antibody response in North Americans after ingestion of Vibrio cholerae. J Infect Dis 1982; 145:465-73.
23. Levine MM, Herrington D, Murphy JR, et al. Safety, infectivity, immunogenicity and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi 541 Ty and 543 Ty, as live oral vaccines in man. J Clin Invest 1987; 79:888-902.
24. Foster RH, Noble S. Bivalent cholera and typhoid vaccine. Drugs 1999; 58:91-6.
25. Woo PCY, Tsoy HW, Wong LP, Leung HCH, Yuen KY. Antibiotics modulate vaccine-induced humoral immune response. Clin Diagn Lab Immunol 1999; 6:832-7.
26. Su-Arehawatana P, Singaraj P, Taylor D, et al. Safety and immunogenicity of different immunization regimens of CVD103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992; 165:1042-8.
27. Suharyono, Simanjuntak C, Witham N, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992; 340:689-94.
28. Gotuzzo E, Butron B, Seas C, et al. Safety, immunogenicity and excretion pattern of single dose live oral cholera vaccine CVD103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993; 61:3994-7.
29. Perry RT, Plowe CV, Koumaré B, et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HW-noninfected adults in Mali. Bull World Health Organ 1998; 76: 63-71.
30. Cryz S, Levine MM, Losonsky J, Kaper JB, Althaus B. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD103-HgR live oral cholera vaccine in Swiss adults. Infect Immun 1992; 60:3916-7.
31. Gendrel D, Sitbon M, Richard-Lenoble D, et al. Etiology of acute infantile gastroenteritis in Gabon. Bull Soc Pathol Exot Filiales 1985; 78:290-5.
32. Agarwal SC, Ganguly NK. Vibriocidal antibodies induced by Yersinia enterocolitica serotype IX. J Hyg 1972; 70:161-9.